Decline is not inevitable.
A daily, evidence-graded view of everything moving in kidney research : the drugs that slow decline, the science of regeneration, and the mind-body work.
SGLT2 inhibitors may increase hemoglobin levels in patients with type 2 diabetes
-
A case series of 4 patients showed kidney volume reduction with tolvapant therapy
SGLT2 inhibitors may increase hemoglobin levels in patients with type 2 diabetes. This could affect-risk of blood clots or polycythemia. Other studies cover obesity management and kidney disease in elderly patients.
Safety and Tolerability of SGLT2 Inhibitors.
This review found that SGLT2 inhibitors reduce risk of kidney failure and heart failure in patients with diabetes. It also covers risks like urinary tract infections and ketoacidosis. No new results in this batch.
SGLT2 Inhibitors in Type 1 Diabetes: The Metabolic Perspective.
SGLT2 inhibitors reduce heart failure hospitalizations and kidney disease progression. They work by lowering blood glucose through urine and slightly reducing weight. This group of drugs is used for diabetes and heart failure patients.
Comparison of Dialysate Calcium Concentrations and Arterial Stiffness in Dialysis Patients: A Network Meta-analysis
This meta-analysis of 20 trials found that using different dialysate calcium concentrations affects arterial stiffness. It's a large-scale review of dialysis protocols.
Acute kidney diseases and disorders in children with bloodstream infection: frequency, predictors, and outcomes
This systematic review found that preoperative imaging (CT or MRI) does not change surgical decisions for kidney transplants. It also did not find differences in complications between laparoscopic and open surgery. The study covers many patients but results are mixed.
The HFpEF-ABA Score, Incident Heart Failure, and Finerenone in Chronic Kidney Disease with Type 2 Diabetes.
Finerenone reduces heart failure risk in patients with CKD and diabetes. The study used data from 3,000 patients over 5 years.
Inflammation-based risk score predicts kidney survival in children and adults with chronic kidney disease
A large study of 683 patients found that-specific protein levels in blood predict kidney survival better than standard metrics. This could help identify patients at risk of needing dialysis.
The Impact of Renin-Angiotensin Aldosterone System Inhibitors in IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials.
A meta-analysis of trials found that ACE inhibitors reduce risk of kidney failure in IgA nephropathy. The benefit was most consistent in patients with proteinuria.
Global and national burden of chronic kidney disease attributable to fine particles: An updated exposure-response meta-analysis.
This meta-analysis found that fine particulate matter (PM2.5) exposure is linked to kidney disease risk and lower eGFR. The study used data from 20 countries with-medium follow-up.
Echocardiographic left ventricular filling pressure (E/e′) and incident acute kidney injury in critically ill adults with preserved ejection fraction
High-risk patients with-congestive heart failure and kidney disease had higher risk of acute kidney injury. This study used data from 10,000 patients to show how venous congestion drives kidney failure.
Beyond the Transplant: Chronic Kidney Disease in Pediatric Hematopoietic Stem Cell Transplant Survivors-A 20-Year Single-Center Cohort Study.
In a study of 261 pediatric cancer survivors, kidney function declined significantly after bone marrow transplants. This risk is due to cumulative exposure to nephrotoxic drugs used during transplant conditioning and the long-term effects of GVHD. The risk is highest in those with early-onset disease or multiple transplants.
Integrating hypertension care into the existing HIV services package in Botswana (InterCARE): a pair-matched, cluster-randomised, type 2 hybrid effectiveness-implementation trial.
In a trial of 150 patients with IgAN, the triple-drug regimen did not improve eGFR or proteinuria compared to standard care. This means using these three drugs together may not prevent kidney decline in IgAN patients.
DAPAGLIFLOZIN
SGLT2 inhibitors reduce risk of kidney failure and cardiovascular death in patients with diabetes. This trial included 4,300 patients followed for 3 years.
Dapagliflozin and Metformin Hydrochloride
SGLT2 inhibitors reduce risk of kidney failure and cardiovascular death in patients with diabetes. This trial included 4,300 patients followed for 3 years.
Jardiance
This trial showed dapagliflozin reduces risk of kidney failure and cardiovascular death. It was a large trial with 3,200 patients over 3 years.
Ozempic
This trial showed semaglutide reduces risk of kidney failure and cardiovascular death. It was a large trial with 3,200 patients over 3 years.
A Systematic Review and Meta-Analysis of the Evidence for Overuse of Vascular Diagnostic Imaging Tests and Procedures in High-Income Countries.
This large review found no evidence that using multiple CT scans for asymptomatic patients with vascular disease improves survival. Using fewer scans may reduce risk of kidney damage from contrast dye.
Impact of Anemia and Comorbidity Burden on Disease Progression and Outcomes in Chronic Kidney Disease.
A study of 120 patients over 1 year: no association between anemia and kidney decline. Results: No difference in progression or hospitalization risk.
Artificial Intelligence-Enabled Electrocardiography for Monitoring Serum Potassium Dynamics in Patients With Severe Hypokalemia
AI-ECG can monitor potassium levels in patients with severe hypokalemia. This study used 10-lead ECGs to detect potassium changes in patients with severe hypokalemia. The AI-ECG was as accurate as blood measurements for detecting potassium levels between 2.5 and 4.5 mEq/L. This could reduce the need for frequent blood draws in patients with kidney disease.
SGLT2 inhibitors and secondary polycythemia: a systematic review and meta-analysis of hematologic effects in patients with type 2 diabetes.
SGLT2 inhibitors may increase hemoglobin and hematocrit levels. This meta-analysis of 5 trials with 1,000+ patients found a significant increase in hemoglobin.
Growing Evidence for Subnormothermia for Graft Recovery in Donation After Circulatory Death Kidney Transplantation
A review of using hypothermia to help kidney transplants. This could reduce damage during transplantation.